NCT01862081 - A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2013

Primary Completion Date

June 9, 2017

Study Completion Date

June 9, 2017

Conditions

Breast Cancer, Non-small Lung Cancer

Interventions

DRUG

Docetaxel

Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.

DRUG

GDC-0032

Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.

DRUG

Paclitaxel

Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.

Trial Locations (14)

3000

UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy, Leuven

23502

Virginia Oncology Associates, Norfolk

33607

Florida Cancer Specialists - Tampa (Dr. MLK Blvd), Tampa

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University Medical Center, Nashville

46010

Hospital Clinico Universitario de Valencia, Valencia

48201

Barbara Ann Karmanos Cancer Institute, Detroit

75231

Texas Oncology, P.A; Baylor Sammons Cancer Center, Dallas

76104

Texas Oncology, P.A. - Fort Worth, Fort Worth

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

M4X 1K9

Princess Margaret Hospital, Toronto

08035

Hospital Universitari Vall d'Hebron, Barcelona